Lungpacer Medical

Lungpacer Medical is a medical device company dedicated to improving respiratory and critical care medicine. Founded in 2009 and headquartered in Vancouver, Canada, the company focuses on designing non-surgical, minimally invasive technologies to ventilate patients more safely and effectively. Their flagship product, the Lungpacer Diaphragm Pacing Therapy System™ (DPTS), is the first minimally invasive, temporary transvenous diaphragmatic neurostimulation system with FDA Emergency Use Authorization (EUA) for use during the COVID-19 pandemic. This system, delivered via the Lungpacer IntraVenous Electrode (LIVE Catheter®), stimulates the diaphragm in conjunction with an invasive mechanical ventilator to help patients wean off the ventilator more rapidly. It is important to note that the DPTS has been authorized for emergency use by the FDA and is not cleared or approved for the indication to assist in weaning patients off ventilators in healthcare settings during the COVID-19 pandemic. Additionally, the company received a Venture - Series Unknown investment on 06 January 2021. The investors for the last investment round are currently unknown.